ArticleCancers2026
Efficacy of Second-Line Lenvatinib After Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara and 1 more
Abstract read
In one paragraphArticle in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Teiji KuzuyaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-2229-990X Hisanori MutoDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Yoshihiko TachiDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0001-9799-2445 Gakushi KomuraDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Takuji NakanoDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Hiroyuki TanakaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Kazunori NakaokaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-7407-1763 Kohei FunasakaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.ORCID 0000-0002-3869-1420 Mitsuo NagasakaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Ryoji MiyaharaDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Eizaburo OhnoDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
atezolizumab plus bevacizumabdurvalumab plus tremelimumabhepatocellular carcinomaimmune checkpoint inhibitorlenvatinibsequential therapytreatment resistanceVEGF inhibition
Identifiers
PMID42449639
PMCPMC13359612
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390